IMAGENT Drug Patent Profile

Which patents cover Imagent, and what generic alternatives are available?

Imagent is a drug marketed by Vesselon Spv Llc and Alliance Pharm and is included in two NDAs.

The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.

Summary for IMAGENT

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	96
Patent Applications:	3,856
DailyMed Link:	IMAGENT at DailyMed

US Patents and Regulatory Information for IMAGENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002		DISCN	No	No
Alliance Pharm	IMAGENT	perflubron	LIQUID;ORAL	020091-001	Aug 13, 1993		DISCN	No	No

Expired US Patents for IMAGENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002	6,280,704
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002	5,605,673
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002	5,798,091
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002	6,280,705
Vesselon Spv Llc	IMAGENT	dimyristoyl lecithin; perflexane	INJECTABLE;INTRAVENOUS	021191-001	May 31, 2002	5,720,938

International Patents for IMAGENT

See the table below for patents covering IMAGENT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	731671
Denmark	0711179
Japan	4229918
China	1182373
Japan	3559849

IMAGENT Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Imagent

Introduction

Imagent, originally approved by the FDA under NDA 21-191, is a key component in the development of novel therapeutic drug complexes, particularly in the realm of immuno-oncology. Here, we delve into the market dynamics and financial trajectory associated with Imagent, highlighting its potential, challenges, and the broader industry context.

Background on Imagent

Imagent Perflexane Lipid Microspheres are microbubble contrast agents used in ultrasound imaging. Recently, Vesselon acquired these microspheres to integrate them into their encapsulated drug/drug platform technology. This acquisition is pivotal for Vesselon's strategy to enable repeated, systemic injections of virus-microsphere complexes, which could revolutionize the treatment of difficult cancers and other diseases[5].

Market Context: Clinical Trial Imaging

The clinical trial imaging market, within which Imagent operates, is experiencing significant growth. This market was estimated at USD 1.23 billion in 2024 and is projected to grow at a CAGR of 7.8% from 2025 to 2030. The growth is driven by the expanding biotechnology and pharmaceutical sectors, along with increasing investments in research and development for new therapeutics[1].

Integration into Clinical Trials

Vesselon's acquisition of Imagent is part of a broader strategy to bring new techniques into clinical trials. The integration of Imagent into Vesselon's portfolio is expected to enhance the safety and efficacy of treatments, particularly in immuno-oncology. This move aligns with the increasing demand for advanced imaging technologies in clinical trials, which is a key driver of the clinical trial imaging market[1][5].

Financial Trajectory: Investment and Funding

The financial trajectory for Imagent and related technologies is marked by significant investment activities. Companies like Vesselon are raising substantial funds to support the development and commercialization of these technologies. For instance, the success of similar radioligand therapies, such as 177Lu-DOTATATE and 177Lu-PSMA-617, has attracted considerable investor interest and capital. These therapies have led to significant valuations and acquisitions, such as Novartis's acquisition of Endocyte for $2.1 billion[2].

Strategic Partnerships and Acquisitions

The market for advanced imaging and therapeutic technologies is highly competitive and characterized by strategic partnerships and acquisitions. Companies are partnering with research institutions and healthcare providers to leverage specialized expertise and evaluate their technologies in real-world clinical environments. The acquisition of Imagent by Vesselon is a strategic move to enhance its capabilities in this rapidly evolving area[1].

Regulatory and Commercial Success

The success of Imagent will depend on its regulatory approval and commercial uptake. Historical examples, such as the approval and launch of 177Lu-DOTATATE, demonstrate that successful navigation of regulatory processes and strong commercial performance can lead to significant financial returns. The FDA approval and subsequent commercial success of such therapies have validated their potential in the eyes of investors and the broader market[2].

Precision Medicine and Personalized Treatments

The rise of precision medicine and personalized treatments is another factor driving the growth of the clinical trial imaging market. Imagent's integration into Vesselon's platform aligns with this trend, as it enables more targeted and effective treatments. The precision medicine market, estimated to be around USD 100 billion, underscores the need for advanced imaging technologies to support individualized treatment approaches[1].

Economic Ramifications

The development and commercialization of drugs like those enabled by Imagent have significant economic implications. The ability to create products for small patient populations changes optimal pricing policies and decisions about which drugs to prioritize. For instance, orphan drugs, which target exceptionally small patient populations, often command higher prices due to their high value to those patients and the limited competition[3].

Generic Entry and Market Exclusivity

The introduction of new formulations, such as those enabled by Imagent, can provide manufacturers with additional years of market exclusivity. This is crucial as it allows companies to maintain a monopoly over brand-name versions of new formulations even after generic versions of the original drug have entered the market. This strategy can add value and convenience for patients while extending the market exclusivity period for the manufacturer[4].

Key Takeaways

• Growing Market: The clinical trial imaging market is growing rapidly, driven by expanding biotechnology and pharmaceutical sectors.
• Strategic Acquisitions: Companies are engaging in strategic partnerships and acquisitions to enhance their capabilities in advanced imaging technologies.
• Regulatory Success: Successful regulatory approval and commercial launch are critical for the financial success of technologies like Imagent.
• Precision Medicine: The rise of precision medicine is driving the demand for advanced imaging technologies.
• Economic Implications: The development of drugs for small patient populations has significant economic ramifications, including higher pricing and extended market exclusivity.

FAQs

Q: What is Imagent and how is it used? A: Imagent Perflexane Lipid Microspheres are microbubble contrast agents used in ultrasound imaging. Vesselon has acquired these microspheres to develop novel therapeutic drug complexes.

Q: How does Imagent fit into the broader market of clinical trial imaging? A: Imagent is part of the growing clinical trial imaging market, which is expected to grow at a CAGR of 7.8% from 2025 to 2030, driven by the expanding biotechnology and pharmaceutical sectors.

Q: What are the financial implications of acquiring and developing technologies like Imagent? A: The acquisition and development of technologies like Imagent involve significant investments. Successful commercialization can lead to substantial financial returns, as seen in the valuations and acquisitions of similar technologies.

Q: How does the rise of precision medicine impact the market for Imagent? A: The rise of precision medicine increases the demand for advanced imaging technologies like Imagent, as these technologies support individualized treatment approaches.

Q: What are the regulatory challenges and opportunities for Imagent? A: Successful regulatory approval is crucial for the commercial success of Imagent. Historical examples show that navigating regulatory processes effectively can lead to significant financial returns and market validation.

Sources

1. Grand View Research - Clinical Trial Imaging Market Size And Share Report, 2030
2. Journal of Nuclear Medicine - Nuclear Medicine and Wall Street: An Evolving Relationship
3. National Bureau of Economic Research - The Economics of Drug Development: Pricing and Innovation in a Changing Market
4. Journal of Managed Care & Specialty Pharmacy - New Drug Formulations and Their Respective Generic Entry Dates
5. BioSpace - Immuno-oncology Innovator Vesselon Expands its Portfolio with Patented Technology to Enable Systemic Viral Therapy with Microspheres and Ultrasound